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ABSTRACT
Hmga2 protein, a transcription factor involved in chromatin architecture, is 
expressed chiefly during development, where it has many key biological functions. 
When expressed in adult tissues from in various organs, Hmga2 is always related to 
cancer development. The role of Hmga2 in skin tumorigenesis is, however, not yet 
understood. We demonstrated that Hmga2 can be found in non-transformed epidermis, 
specifically located to the membrane of keratinocytes (KCs) in epidermis. Ex vivo 
culture of KCs and development of skin carcinomas in DMBA and TPA mouse models 
was associated with translocation of the Hmga2 protein from the membrane into the 
nucleus, where Hmga2 induced its own expression by binding to the Hmga2 promoter. 
Panobinostat, an HDAC inhibitor, downregulated Hmga2 expression by preventing 
Hmga2 to bind its own promoter, and thus inhibiting Hmga2 promoter activity. Hmga2 
translocation to the nucleus could in part be prevented by an inhibitor for ROCK1. Our 
findings demonstrate that upon program of benign papilloma to malignant cSCC of skin 
tumorigenesis, Hmga2 translocates in a ROCK-dependent manner from the membrane 
to the nucleus, where it serves as an autoregulatory transcription factor, causing cell 
transformation.
INTRODUCTION
Cutaneous squamous cell carcinoma (cSCC), 
the second most frequent skin cancer, often arises from 
the progression of benign lesions [1]. This progression 
is believed to be due to sequential DNA mutations in 
oncogenes and tumor suppressor genes including TP53, 
NOTCH1 and CDKN2A [2]. Protein mislocalization 
also plays an important role in cancer initiation and 
progression. For instance, translocation of NF-kB and 
beta-catenin from the cytoplasm to nucleus is frequently 
seen in cancer cells [3]. However, the molecular 
underpinnings that drive cSCC initiation, progression, and 
metastasis are still not fully understood, a prerequisite for 
the development of better therapeutic options [4].
High mobility group AT-hook 2 (Hmga2) is a 
member of the HMG family of proteins. Hmga2 was 
first described in 1991 [5] as a nuclear architectural 
protein that interacts with the minor groove of many 
AT-rich promoters and enhancers through AT-hooks [6]. 
The molecule is widely expressed in undifferentiated 
cells during embryogenesis, becomes more restricted 
as fetal development progresses [7, 8] and is limited to 
the mesenchyme in adults [9]. The promoter of Hmga2 
contains Sp1, Sp3 and RUNX1 binding sites [10, 11], and 
the 3′ untranslated region (UTR) contains bindings sites 
from multiple miRNAs, including miRlet-7, miR10A 
and miR21 [12, 13]. Hmga2 levels were shown to be 
regulated by ROCK inhibitors, causing shortening of the 
poly (A) tail via let-7 [14]. In addition, histone deacetylase 
inhibitors (HDACI) such as panobinostat, Sirtuin 6 and 
trichostatin A significantly reduced the steady-state level 
of Hmga2 through let-7, Sp1 and Sp3 [4, 10, 15].
Hmga2 also plays crucial roles in neural stem cell 
[16] and hair follicle stem cell [17] selfrenewal, as well as 
in adult somatic reprogramming [18]. In addition, Hmga2 
plays a role in a variety of malignant tumors, including 
colorectal, breast, lung, prostate and bladder cancer as 
well as melanoma [21–26]. However it is not known if 
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the role of Hmga2 during cSCC initiation and promotion. 
Given its critical roles in several other 
developmental systems including malignancies we 
therefore investigate Hmga2 function in the context of the 
well-defined multistage model of cutaneous carcinogenesis 
in mice. We made the surprising discovery that Hmg2 was 
expressed in the cell membranes in normal epidermis and 
freshly isolated epidermal keratinocytes. Hmga2 rapidly 
translocated to the nucleus upon cell culture and during 
development of cSCCs. We examined the molecular 
mechanism regulating this translocation in vitro, ex vivo, 
and in vivo. Together, these studies demonstrated that 
Hmga2 translocation functions in an auto-regulatory loop 
associated with the induction of cSCCs.
RESULTS
Hmga2 expression and cellular localization in 
keratinocytes and skin tumor development
We isolated keratinocytes (KCs) from mouse skin 
and isolated KC stem cells based on CD49f and CD34 
expression. RT-qPCR analysis demonstrated that Hmga2 
transcript levels were significantly higher in CD49f+/
CD34+ compared with CD49f+/CD34− cells; while 
transcript levels for the Hmga2-pseudogene (Hmga2-ps1) 
were not enriched in the CD49f+/CD34+ compared with 
the CD49f+/CD34− fraction (Figure 1A). We then cultured 
KCs for 5 days and up to 12 passages. Hmga2 transcripts 
significantly increased in KCs upon culture (Figure 1B, 
Supplementary Figure 1A), while CD34 expression 
decreased, and expression of Hmga2-ps1 and Hmga1 was 
unchanged (Figure 1B, Supplementary Figure 1B and 1C). 
Because Hmga2 transcript levels increased 
significantly during KC culture, we determined the Hmga2 
promoter activity and whether Hmga2 might regulate Hmga2 
promoter activity. For this we co-transfected the full-length 
promoter of Hmga2 upstream of a luciferase cassette together 
with Hmga2 cDNA in 293T and KCs. Luciferase activity 
increased to 44% and 48%, respectively in 293T cells and 
KCs (Figure 1C). We further examined if Hmga2 directly 
binds to the Hmga2 promoter (base pairs [− 800 to + 197] 
relative to the TSS) by ChIP followed by qPCR. These 
studies demonstrated that compared with rabbit IgG, anti-
Hmga2 ChIP significantly enriched the Hmga2 promoter 
region in cultured keratinocyte cells (Figure 1D, 1E).
As Hmga2 appeared to play an autoregulatory 
function following culture of KCs, we next determined the 
location of Hmga2 in fresh and cultured KCs. Unsorted 
and cultured KCs were immunostained with Hmga2 
and CD34 antibodies. Hmga2 was detected in the cell 
membrane of 44.2 ± 9.5% % of KCs, which did not co-
localize with CD34 protein staining, (Figure 1F). Western 
blot of membrane and non-membrane fractions further 
confirmed the membranous vs non-membrane location of 
Hmga2 protein in freshly isolated KCs (Figure 1G). Flow 
cytometry showed that more than 30% KCs expressed 
membrane-specific Hmga2 (Figure 1H), Hmga2 expressed 
in all permeabilized passage 12 KCs while only less 5% 
passage 12 KCs expressed Hmga2 without permeabilized 
(Figure 1I,1J). After KCs were cultured for 5 days, Hmga2 
protein could be detected both in the cell membrane 
(Figure 1Ki), throughout the entire cell (Figure 1Kii) 
and in the nucleus (Figure 1Kiii), while Hmga2 protein 
could only be detected in the cell nucleus in KCs (that 
stained positive for keratin 14, Supplementary Figure 2A) 
at 12 passage (Figure 1L). Thus, upon culture of KCs, 
Hmga2 translocated from the membrane to the nucleus, 
where it functions in an autoregulatory loop. We also 
assessed the presence of Hmga2 and CD34 in normal 
mouse skin. CD34, but not Hmga2 staining was seen in 
the hair follicle bulge, while Hmga2 staining was found 
in the epidermis, where it was located in the membrane of 
epidermal epithelial cells (Figure 1M). Hmga2 protein was 
also detected in the cell membrane of esophageal epithelial 
cells (Supplementary Figure 2B and 2C).
Interestingly, when Hmga2 staining was performed 
on mouse skin papilloma tissue (Figure 1N), Hmga2 was 
also found in the nucleus in most cells (Figure 1O) while 
Hmga2 was cell membrane associated in a few cells 
(Figure 1Oi). In carcinomas (Figure 1P), Hmga2 was 
found only in the nucleus (Figure 1Q) of K14 positive cells 
(Supplementary Figure 2D and 2E), indicating that Hmga2 
also translocated from the membrane to the nucleus during 
carcinoma development.
To understand the discrepancy between Hmga2 
transcript and protein levels in CD34+ KC stem cells, we 
hypothesized that miR let-7 members, known to bind to the 
3′UTR of Hmga2, might inhibit protein expression [12]. 
Therefore, RT-qPCR was performed to measure levels of 
let-7 miRNAs. We found that all miRNAs from the let-7 
family assessed were significantly more expressed in the 
CD49f+/CD34+ cell fraction compared with unsorted KCs 
and the CD49f+/CD34− fraction (Figure 1R), suggesting 
that Hmga2 protein levels in keratinocyte stem cells 
selected from KCs by FACS, and located in the hair follicle 
bulge, might be inhibited by let-7 miRNAs. Thus, Hmga2 
protein levels in hair follicle stem cells may be regulated 
by Let7-miRNAs.
Panobinostat affects keratinocyte proliferation 
as well as transcription and cellular localization 
of Hmga2, during skin tumor development
HDACIs such as panobinostat can inhibit Hmga2 
gene expression in NIH3T3, F9, Hela, liver cancer cell 
lines and human cord blood-derived multipotent stem 
cells [10, 15, 27]. To determine if panobinostat is capable 
of regulating endogenous Hmga2 gene expression in the 
skin, we performed Hmga2 RT-qPCR and protein analysis 
following treatment of freshly isolated KCs cultured with 
either DMSO alone or 20 nM and 200 nM panobinostat, 
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dissolved in DMSO. Hmga2 levels were significantly 
reduced after treatment with 200nM panobinostat for one 
day compared with DMSO control cultures (Figure 2A, 2B). 
As expected, panobinostat significantly induced levels of 
acetyl histone 3 (Supplementary Figure 3A). To further 
demonstrate that panobinostat regulated Hmga2 gene 
transcription, KCs were pre-treated with the transcription 
inhibitor, actinomycin D (Act-D), for 30 min prior to 
addition of either panobinostat or DMSO [10]. RT-qPCR 
analysis demonstrated that addition of Act-D to Panobinostat 
further decreased Hmga2 mRNA levels (Supplementary 
Figure 4A) suggesting that panobinostat inhibits Hmga2 
gene transcription, but not to the same extent as Act-D. We 
also assessed expression levels of the let-7 miRNA family 
in response to panabinostat. As expected, no significant 
changes were found, consistent with the notion that let-7 
miRNAs regulate translation and not transcription of 
Hmga2 (Supplementary Figure 3B). To further substantiate 
the decreased transcription of Hmga2 in response to 
panabinostat, we repeated the Hmga2 luciferase promoter 
studies and Hmga2 ChiP-Seq studies in the presence 
of panabinostat. We found that the Hmga2 promoter 
activity was significantly repressed after treatment with 
panobinostat compared with DMSO treatment (Figure 2C), 
and that enrichment of the Hmga2 promoter by Hmga2 
ChiP-seq was significantly reduced in KCs cultured with 
200 nm panobinostat compared with DMSO (Figure 2D). 
Thus, the HDACi, Panabinostat, significantly decreased 
transcription of Hmga2, by preventing binding of Hmga2 
to it’s own promoter.
We next evaluated the effect of panobinostat 
on the intracellular protein distribution of Hmga2 in 
cultured KCs. Consistent with the transcript levels, 
Hmga2 protein levels were significantly downregulated 
one day after treatment. Interestingly, aside from 
the effect of Panobinostat on Hmga2 transcription, 
Panobinostat also caused Hmga2 protein to be re-
located from the nucleus to cell body of cultured 
KCs (Figure 2E, 2F). The results were similar for 
unsorted KCs (Supplementary Figure 3C–3E). 
To further investigate the role of panobinostat in the 
cellular distribution of Hmga2, we performed skin organ 
cultures. In uncultured skin, distribution of Hmga2 
was in the cellular membrane (Figure 2G). However, 
two days after skin organ culture, Hmga2 redistributed 
into the entire cell (Figure 2H–2Hiii), similar to what 
we demonstrated for isolated KCs. However, when 
Panobinostat in stead of DMSO was added to the skin 
organ cultures, Hmga2 remained excluded from the 
nucleus of epithelial cells (Figure 2I–2Iiii), in line with 
what we demonstrated for isolated KCs in culture. 
We also treated mice with papillomas created using a 
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Figure 1: Hmga2 can be expressed as a non-nuclear protein in the adult organs. (A) Hmga2 and Hmga2-ps1 mRNA levels were 
assessed by qRT-PCR in unsorted and sorted KCs by CD34 and CD49f antibodies (n = 3). (B) Hmga2, Hmga2-ps1 and CD34 mRNA levels 
were assessed by qRT-PCR in unsorted KCs, day5 cultured KCs and long-term cultured KCs (passage 12). (C) 293T and KCs cell lines were 
transfected with pGL3, full-length Hmga2 promoter-luciferase construct (pGL3-Hmga2 promoter), and luciferase assays were performed 48 
hours after transfection. Co-expression was conducted with Hmga2 expression vectors. Error bars indicate standard deviation (n = 3). (D) 
Agarose gel electrophoresis for enriched GAPDH promoter at 30 cycles. (E) ChIP assay for Hmga2 binding to the Hmga2 promoter. (F, K, L) 
unsorted (F), short-term cultured (day 5) (K) and long-term cultured KCs (passage 12) (L) were fixed, and subjected to immunofluorescence 
using Hmga2 and CD34 antibodies. Nuclei were stained using Hoechst33342, Hmga2 green, CD34 red (n = 3). Ki-Kiii. higher magnification 
showing the expression of Hmga2 at membrane, entire cells and nucleus. (G) Hmga2 protein expression in KCs from membrane and non-
membrane. Membrane (M) and non membrane (non-M) fractions containing equal amounts of protein. (H–J) Hmga2 protein expression 
determined by flow cytometry. (H) unsorted KCs; (I) passage 12 KCs; (J) permeabilized passage 12 KCs. (M, O, Q) Normal skin tissue (M), 
papilloma (O) and carcinoma tissue (Q) were fixed, and subjected to immunofluorescence using Hmga2 and CD34 antibodies. Nuclei were 
stained using DAPI, Hmga2 red, CD34 green (n = 3). Mi. Higher magnification showing the expression of Hmga2 in the membrane in normal 
skin tissue. Oi. Higher magnification showing the expression of Hmga2 in membrane (red arrowhead) and nucleus in papilloma. (N and P) 
Hematoxylin and Eosin (H&E) staining for skin tissue from papilloma and carcinoma. R. let-7 family RNA were assessed by qRT-PCR in 
unsorted and sorted KCs by CD34 and CD49f antibodies (n = 3). The scale bar size 50 mm. *P < 0.05. **P < 0.01.
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DMBA/TPA protocol with panobinostat [28]. Panobinostat 
was given i.p. at 15 mg/kg 3 times a week (M/W/F) for 
3 weeks when 1 mm benign papilloma formed. Hmga2 
translocation from the cytoplasm to the nucleus in the 
epidermis was also inhibited by panabinostat. More than 
50% of the cells in the papillomas of vehicle control 
treated mice contained nuclear Hmga2 (Figure 2J, 2K), 
while in panobinostat treated mice, there were either no or 
lower levels of Hmga2 protein in the nucleus, and in some 
cells Hmga2 was detected in the membrane (Figure 2L and 
2M–2Mi). In addition, panobinostat affected papilloma 
growth: although the number of papules and small size 
papillomas (1–2 mm) was not different between mice 
treated with panobinostat and vehicle control, no medium 
size (3–5 mm) papillomas were formed in mice treated with 
panobinostat (Figure 2N, Supplementary Figure 5A–5C). 
In addition, KI67 positive cells in papillomas were 
significantly decreased in the panobinostat treated group 
(Supplementary Figure 6A and 6B), demonstrating that 
Panobinostat also prevented translocation of Hmga2 
in vivo in developing tumors, which was associated with a 
decreased proliferation of transformed cells. 
Panabinostat-mediated inhibition of Hmga2 
translocation occurs via ROCK1
To understand how panobinostat inhibited Hmga2 
translocation, we assessed the effect of panobinostat 
treatment on ROCK1 mRNA and protein levels as 
inhibition of ROCK can enhance let-7 repression (14). 
Treatment of KCs with 200 nM panobinostat significantly 
reduced both transcripts and protein levels of ROCK1, 
suggesting that Panobinostat may at least in part affect 
Hmga2 via inhibiting ROCK1 expression (Figure 3A–3B). 
As Y27632 is a ROCK1 inhibitor, we treated cultured 
KCs with or without Y27632. RT-qPCR analysis showed 
significantly lower Hmga2 transcript levels in KCs 
cultured for 10 days with Y27632 compared to control 
no-Y27632 group (Figure 3C). Moreover, Hmga2 protein, 
present in the nucleus and cell of unsorted KCs, cultured 
for 10 days without Y27632, remained outside of the 
nucleus in the majority of KCs treated with Y27632 
(Figure 3D–3F). Similar results were seen for passage 12 
KCs (Supplementary Figure 7A–7C). Consistently, when 
100 uM Y27632 was added to skin organ culture, Hmga2 
did not relocate from the cell membrane in fresh organs 
to the whole cell after two days of culture in the presence 
of Y27632 (Supplementary Figure 8 without treatment; 
Figure 3G–Giii with medium; Figure 3H–Hiii with 
medium+Y27632), providing functional evidence for the 
role of ROCK-1 in Hmga2 intracellular localization. To 
further prove the role of ROCK1 in Hmga2 translocation, 
we created ROCK1-knock-down (KD) KCs (Figure 3I). 
Immunostaining demonstrated that Hmga2 was found in 
the entire cell in most KD cultured KCs while only in the 
nucleus of control cultured KCs (Figure 3J, 3K), providing 
genetic evidence that ROCK1 is involved in relocalization 
of Hmga2 from the cell cytoplasm/membrane to the 
nucleus.
DISCUSSION
Increasing evidence implicates both molecular 
changes and protein mislocalization as contributing to 
carcinogenesis. Hmga2, which is widely expressed in 
undifferentiated cells during embryogenesis, is expressed 
only in the mesenchyme in adults [9]. In postnatal life, 
aside from playing a role in stem cell selfrenewal [16, 17], 
Hmga2 was shown to play an important role in a variety 
of malignant tumors [21–26]. Whether Hmga2 is involved 
in skin cancer development has not yet been addressed.
We here demonstrate that Hmga2 is expressed 
in non-transformed keratinocytes throughout the 
skin (and esophagus), located to the cell membrane. 
We demonstrated further that upon induction of cell 
proliferation in vitro, and during the development of cSCC, 
Hmga2 protein relocates to the nucleus, where it activates 
expression of Hmga2 protein by binding to and activating 
the Hmga2 promoter. This process can be inhibited by the 
HDACi, panabinostat, as well as by inhibiting ROCK1.
High levels of Hmga2 have been observed in several 
mesenchymal tumors and various human carcinomas [29], 
where it is expressed mainly detected in the cell nucleus. 
In addition, during development, Hmga2 is also chiefly 
located in the nuclear compartment. Here we demonstrate 
that not only in postnatal quiescent KCs, Hmga2 can be 
found, not in the nucleus but in the cell membrane, but 
also we observed increased expression of Hmga2 as well 
as translocation of Hmga2 to the nucleus upon induction 
of KC cell proliferation. This was observed using 
isolated KCs in vitro, where Hmga2 was fully nuclear 
after long-term culture and in skin organ cultures, where 
Hmga2 was found throughout the cells 2 days following 
culture. Importantly, we also demonstrated that and upon 
transformation to skin papillomas and carcinomas in vivo, 
Hmga2 initially relocated throughout the cell with still 
some cell membrane associated Hmga2 in papillomas, but 
relocated to the nucleus in carcinomas. The role of Hmga2 
in the cell membrane is currently not known. However, our 
studies indicate that relocation of Hmga2 to the nucleus, 
which is associated with increased cell proliferation (Ki67 
positive cells) (Supplementary Figure 6A and 6B). 
High-level expression of Hmga2 in mesenchymal 
and epithelial cancer cells [31] has been linked to 
rearrangements and mutations of HMGA caused by 
chromosomal translocations involving the HMG 
locus [31]. To determine the mechanism underlying 
the increased Hmga2 expression levels in proliferating 
and transforming KCs, we assessed that Hmga2 has an 
autoregulatory function by promoter-luciferase assay 
and ChIP-PCR. Our data suggest that when KCs start to 
proliferate, Hmga2 translocates to the cell nucleus where 
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Figure 2: Hmga2 translocation to nucleus can be inhibited by panobinostat. (A) Hmga2, Hmga2-ps1 mRNA levels were 
assessed by qRT-PCR in KCs treated with 20 nM, 200 nM panobinostat. (B) Analysis of Hmga2 expression by western blot in KCs 
after treatment with 200 nM panobinostat. (C) Hmga2 promoter activity in KCs after treatment with panobinostat. KCs cell lines treated 
with DMSO or 200 nM panobinostat and were transfected with pGL3, full-length Hmga2 promoter-luciferase construct (pGL3-Hmga2 
promoter), and luciferase assays were performed 48 hours after transfection. (D) ChIP assay for Hmga2 binding to the Hmga2 promoter. 
KCs cells were cultured with DMSO or 200 nM panobinostat for two days. Cells were harvested and ChIP was performed with an isogenic 
or anti-Hmga2 antibodies. Enrichment for the Hmga2 promoter in the precipitated DNA was analyzed by qPCR using primers that flank the 
distal promoter region. Results from triplicate experiments are shown as fold change of DNA enrichment. (E and F) KCs treated with DMSO 
and panobinostat, and subjected to immunofluorescence using Hmga2 antibodies. Nuclei were stained using Hoechst33342, Hmga2 green 
(n = 3). (G, H and I) Ex vivo cultured skin tissue treated with DMSO and panobinostat were fixed, and subjected to immunofluorescence 
using Hmga2 antibodies. Nuclei were stained using DAPI, Hmga2 red. Hi-Hiii. Higher magnification showing the expression of Hmga2 
in the nucleus and cytoplasm. Ii-Iiii. Higher magnification showing the expression of Hmga2 in the cytoplasm. (K and M) Papillomas 
from mouse treated with vehicle and panobinostat were fixed, and subjected to immunofluorescence using Hmga2 antibodies. Nuclei were 
stained using DAPI, Hmga2 red. (J and L) H&E staining for papillomas from mice treated with vehicle and panobinostat. (N) Papules and 
papillomas number from SKH mouse after treated vehicle and panobinostat at 3 weeks. The scale bar size 50 mm. * P < 0.05. **P < 0.01.
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Figure 3: The inhibition of Hmga2 translocation is through ROCKs. (A) ROCK1 mRNA levels were assessed by qRT-PCR in 
KCs treated with 200 nM panobinostat. (B) Western Blot analysis of ROCK1 expression in KCs after treated with panobinostat. (C) Hmga2, 
Hmga2-ps1 mRNA levels were assessed by qRT-PCR in unsorted KCs, day 10 cultured KCs without Y27632 and day 10 cultured KCs 
treated with 10 uM Y27632. (D–F) Unsorted, day 10 cultured KCs without Y27632 and day 10 cultured KCs treated with Y27632 were 
fixed, and subjected to immunofluorescence using Hmga2 and CD34 antibodies. Nuclei were stained using Hoechst33342, Hmga2 green, 
CD34 red (n = 3). (G) KCs were transduced with either ROCK1 (sh-ROCK1-3 and sh-ROCK1-5) or mock shRNA lentiviral vectors. 
ROCK1 protein expression was examined by immunoblot. (H and I) Hmga2 expression in the KCs with mock and ROCK1 knock-down. 
Nuclei were stained using Hoechst33342, Hmga2 green (n = 3). (J, K) Ex vivo cultured skin tissue treated with medium (J) and 100 µM 
Y27632 (K) were fixed, and subjected to immunofluorescence using Hmga2 antibodies. Nuclei were stained using DAPI, Hmga2 red. 
Ji–Jiii. Higher magnification showing the expression of Hmga2 in the nucleus and cytoplasm. Ki-Kiii. Higher magnification showing the 
expression of Hmga2 in the cytoplasm. The scale bar size 50 mm. *P < 0.05. **P < 0.01.
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it causes increased Hmga2 expression by directly binding 
and activating it’s own promoter.
In line with the description that Hmga2 may play a 
role in hair follicle stem cell selfrenewal [16], we found 
higher levels of Hmga2 transcripts in CD34+/CD49f+ 
cells isolated from the keratinocyte fraction of the skin. 
However, we could not detect Hmga2 protein in the 
CD34+ fraction. This discrepancy between transcript 
and protein levels in hair follicular stem cells might be 
explained by the fact that the let-7 was significantly higher 
expressed in CD34+/CD49f+ cells compared with CD34+/
CD49f- depleted fraction. This is consistent with the fact 
that there are seven let-7 binding sites in the Hmga2 3′-
UTR, and that during development expression of let-7 is 
inversely correlated with expression of Hmga2, likely due 
to post-transcriptional modification of Hmga2 protein via 
let-7 miRNA [12].
Aside from the transcriptional regulation of Hmga2 
by Hmga2 itself, as we demonstrate here, and the post-
transcriptional regulation by let-7. We also demonstrate 
that the HDACi, panabinostat, can also decrease the 
autoregulatory activation of Hmga2 expression. Although 
inhibition of Hmga2 expression by panobinostat was 
shown to be mediated by affecting levels of let-7 in the 
liver cancer cells [15], we did not find changes in let-7 
expression in the KCs described here (Supplementary 
Figure 3B). White, et al., found that Hmga2 was 
dispensable for cSCC formation as tumors developed in 
Hmga2 KO mice also overexpressing KRasG12D. In their 
study they found that loss of Hmga2 was associated 
with increased levels of Hmga1, and suggested that 
Hmga1 could compensate Hmga2 loss [32]. Differences 
between the two studies might be the dosage of DMBA/
TPA used to create the mouse model. Hmga1 expression 
was unchanged in our study following treatment with 
panabinostat, suggesting that Hmga1 may not compensate 
from the depressed levels of Hmga2 induced by 
panobinostat (Supplementary Figure 1D). 
A final question we addressed is the mechanism by 
which treatment with panobinostat prevented translocation 
of Hmga2 to the nucleus, and hence the auto-regulation 
of Hmga2. Yoshikawa et al., described that inhibition 
of ROCK can enhance let-7 repression [14], while 
Zhao et al., demonstrated that and ROCK1 can induce 
ERK nuclear translocation [33]. We here demonstrated 
that panobinostat inhibits ROCK1 expression, and that 
inhibition of ROCK by the Y27632 inhibitor could prevent 
Hmga2 relocation to the nucleus in KCs and skin organ 
culture in a concentration dependent manner. Further using 
ROCK1-KD cultured KCs, Hmga2 expression was found 
the entire cell, but not exclusively in the nucleus. This 
suggested that the inhibition of panobinostat on Hmga2 is 
at least in part through ROCK1. 
Overall, these findings demonstrated that Hmga2 is 
expressed in the membrane of KCs, but translocates to the 
nucleus upon culture of isolated KCs or KCs in the context 
of skin organ culture. In addition, Hmga2 translocates to 
the nucleus during malignant transformation. Hmga2 can 
in these setting activate it’s own receptor, causing elevated 
levels of Hmga2. All these processes can be inhibited 
by treatment of KCs, skin organ cultures or of DMBA/
TPA treated mice with the HDACi, panabinostat, which 
prevents binding of Hmga2 to it’s promoter and prevents 
relocation of Hmga2 to the nucleus, the latter in part by 
inhibiting Rock. These studies demonstrate therefore 
a prominent role of Hmga2 in cSCC development, 
even if further studies will be needed to understand the 
function of Hmga2 in the membrane of quiescent KCs 
and the complete mechanism of Hmga2 translocation. 
These studies also suggest a possible role for HDACi in 
treatment of cSCC.
MATERIALS AND METHODS
Keratinocyte cell culture, transfection and 
sorting 
Primary KCs were harvested from the backs of adult 
C3H mice at 54 ± 2 days and KC cell lines arising from 
these cultures were maintained in Morris II medium [34]. 
Cell lines were periodically tested for Mycoplasma. 
No other authentication was performed. For transient 
transfection in HEK293 (ATCC, cat no.SD-3515,) 
and in the KC cell line, cells were transfected using 
VIROMER RED (Lipocalyx GmbH, Germany). For 
ROCK1 knockdown in KCs, cells were transfected with 
pooled shRNA reagent (All shRNAs were obtained from 
the BioMedical Genomics Center at The University of 
Minnesota). The negative control vector was the pLKO.1 
vector backbones that has no hairpin insert. Primary KCs 
were stained with antibodies to CD34 (rat anti-mouse 
CD34-FITC, BD Pharmingen); rat anti-mouse CD49f-PE 
[(alpha-6 integrin), BD Pharmingen] and stem cell fraction 
(CD49f+CD34+) and stem cell depletion fraction (CD49f 
+CD34−) were sorted using Fluorescence Activated Cell 
Sorting (FACS) as previously described [28].
RNA extraction and quantitative RT-PCR
RNA was isolated using the RNeasy Micro-kit 
(Qiagen), and DNase treatment with the Turbo DNAse 
kit (Ambion). cDNA synthesis was performed from 
1 µg of RNA with Superscript III First-Strand synthesis 
system (Invitrogen). Quantitative Real time PCR (qRT-
PCR) was performed using the Platinum SYBR green 
qPCR Supermix-UDG (Invitrogen) and the Eppendorf 
realplex/ABI 7000 (Eppendorf, Applied Biosciences). 
Relative gene expression was calculated by the 2(- DDCt) 
method compared to control group, using GAPDH as 
housekeeping gene. The list of primers used can be found 
in Supplementary Table 1.
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Immunofluorescence assay
KCs were fixed using 10% Neutral Buffered 
Formalin (Fisher Scientific) for 15 min at room 
temperature (RT). Permeabilization was done for 10 min 
using a phosphate buffered saline (PBS) containing 0.1% 
Triton X-100 (PBST) (Acros Organics). PBST, containing 
5% normal horse serum (Jackson), was used for blocking 
for 30 min at RT. The cells were then incubated with 
the mixture of primary antibodies or appropriate isotype 
control antibodies diluted in PBS containing 5% horse 
serum, and incubated overnight at 4°C After 3 washes 
in PBS, the cells were incubated with the mixture of 
respective Alexa dye conjugated secondary antibodies 
(Invitrogen) for 30 mins and Hoechst333425 dye (Sigma) 
for 5 min at RT. The list of primary and secondary 
antibodies used can be found in Supplementary Table 2. 
To enumerate the percentage of cells that stained positive, 
cells were imaged using a Zeiss Axioskop microscope and 
AxioVision Version Rel 4.0 software was used to quantify 
the number of positive cells in 5 to 10 random areas per 
slide and per condition. 
Skin tissues were collected and fixed with 10% 
formalin for at least 24 hours and then put into 70% 
ethanol at 4°C. Paraffin-embedded skin sections were 
rehydrated in a series of ethanol solutions and antigen-
retrieved with antigen unmasking solution (H3300, Vector 
Laboratories, Inc. Burlingame, CA 94010) in a microwave 
oven for 5 minutes. The slides were then incubated with 
the rat primary antibody, overnight at 4°C, followed by 
washing and subsequent incubation in secondary antibody 
( Invitrogen, Alexa ) in a 1:500 dilution. The slides were 
washed and incubated in the VECTASHIELD (H-1200, 
Vector Laboratories).
Plasma membrane extracts
Plasma membrane extracts of unsorted KCs were 
prepared using a plasma membrane protein extraction kit 
(Biovision). Cells were harvested at 5–10 × 108 in cold 
PBS, spun down, washed once in cold PBS and frozen. 
Homogenization (with Dounce homogenizer) and plasma 
membrane protein extraction were performed according 
to the manufacturer›s instructions using buffers included 
in the kit. Plasma membrane fraction was tested for the 
presence of plasma membrane markers such as Na-ATPase.
Western blotting
Cells were harvested and frozen at −80°C. Protein 
extracts were prepared in a RIPA buffer (Sigma) plus 
proteinase inhibitor and phosphatase inhibitor (both 
from Roche Diagnostics). Equal amounts of protein 
lysate (20 to 40 mg) were separated on NuPAGE gels 
(Invitrogen). Proteins were transferred onto Immobilon-P 
transfer membranes (Millipore Corp.) and analyzed 
by Western blotting using antibodies recognizing the 
following proteins: Hmga2, Na-K ATPase, Rock1, Histone 
H3, Acetyl-Histone H3 and beta-actin were purchased 
from Cell Signaling Technology, another Hmga2 Ab 
from R&D. Images were visualized with an enhanced 
chemiluminescence detection kit (ECL-Plus; Amersham 
Pharmacia Biotech) and the ImageQant LAS 4000 
imaging system (GE Healthcare life Sciences). Results of 
Western blot analyses were representative of two to four 
independent experiments.
Luciferase reporter assay
Luciferase reporter plasmids driven by the Hmga2 
promoter (named pHmga2-Luc) were constructed by 
inserting the −800 to +197 Hmga2 promoter sequence [11] 
into the pGL3 luciferase reporter vector or a combination 
of pLL3.7-Hmga2 expression constructs. The promoter 
and Hmga2 CDS was confirmed by sequencing. Mouse 
KCs were used to assess the promoter activation. After 
mouse KCs (250,000/cm2) were treated with DMSO and 
200 nM panobinostat, and then transfected with each 
of the reporter vectors together with pRL-tk plasmid 
(Promega) (at 1/10 of the DNA amount for the test vector) 
and Renilla luciferase as an internal control for possible 
variation in transfection efficiency. Cells were harvested 
48 h after transfection with VIROMER red transfection 
reagent (Lipocalyx), and firefly and Renilla luciferase 
activities in the lysates tested using the Dual-Luciferase 
Reporter Assay System (Promega) on a Luminoskan 
Ascent (Labsystems). The ratio between Firefly and 
Renilla luciferase activity was obtained for each sample. 
Relative luciferase units were calculated via normalization 
of each of the ratios for all groups by the average ratio for 
the promoterless group.
Flow cytometric analysis
Surface and intracellular staining with unsorted KCs 
and passage 12 KCs were performed. Flow cytometric 
analyses were performed with Flowjo (Tree Star). Single 
cells from unsorted KCs, passage 12 KCs and permeabilized 
passage 12 KCs by 90% acetone was detected. Cells were 
stained with the Hmga2 (Cell Signaling Technology) for 
90 mins under 4 degree and add Alex488 (0.2 mg/ml, 
Invitrogen) for another 60min under 4 degree. 
Chromatin immunoprecipitation-qPCR 
Chromatin isolation and IP were performed 
according to the instructions from the Transcription Factor 
ChIP (Chromatin immunoprecipitation) kit (Diagenode). 
Chromatin was isolated from nearly 5 × 107 KCs treated 
with or w/o panobinostat. Antibodies against Hmga2 
(Gene Tex) or an isogenic antibody (Santa Cruz) were used 
at 2 mg per IP reaction. Purified DNA was used as template 
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for qRT-PCR using Platinum SYBR green to amplify the 
Hmga2 promoter or GAPDH promoter(Supplementary 
Table S1). The PCR product size was 94 bp (Hmga2 
promoter) and 104 bp (Gapdh promoter). The following 
PCR conditions were used, 3 min at 95°C and 40 cycles of 
15 s at 95°C, 45 s at 60°C and 1 min at 95°C.
Organotypic Skin Culture
Female C3H mice were bred at University of 
Minnesota, Hormel institute. Cages were changed twice 
weekly; food and water were available ad libitum. 
Untreated mice 7 to 9 wk of age were euthanized by 
CO2 by inhalation followed by cervical dislocation, 
clipped, depilated with Nair (Carter Products, Division of 
Carter-Wallace, Inc., New York, NY), and washed with 
povidone-Iodine (American Sterilizer Co., Erie, PA) and 
70% ethanol. The dorsal skin was excised and placed in 
sterile calcium-and magnesium-free Dulbecco’s phosphate 
buffered saline (Gibco) with 100 mg/liter of gentamicin 
sulfate (Whittaker M.A. Bioproducts). Each piece of 
skin was placed in a sterile petri dish (Corning) and the 
subcutaneous fat and muscle were removed by scraping 
with a scalpel with a number 22 blade. Pieces of 1 mm2 
were cut with a new sharp blade (a clean cut with very 
sharp blade seemed to be important for subsequent 
epidermal outgrowth) and placed onto 100-mm Corning 
tissue culture dishes (Corning biocat) and incubated with 
Morris II medium plus DMSO or panobinostat. 
Mice
Female SKH-1 mice (6 weeks old) were purchased 
from Charles River Laboratories (Wilmington, MA). 
The animals were housed five per cage at 22 ± 10°C 
and 50 ± 10% relative humidity and subjected to a 
12 h light/ 12 h dark cycle in the College of Pharmacy 
animal facility. They were acclimatized for 1 week 
before use and provided food and water ad libitum. Non-
melanoma skin cancer was induced by one time treatment 
of Dimethylbenz(a)anthracene (DMBA; 100 nmol in 
200 microliters of acetone) to the dorsal skin. Upon 
treatment, the mice were placed in disposable cages where 
they remained for 1 week. During this time, the mice 
continued to live in SPF housing. One week later, mice 
received twice weekly treatments (Tuesday/Thursday) 
with the tumor promoter 12-O-tetradecanoylphorpol-
13-acetate (TPA: 5 nmol in 200 microliters of acetone) 
for up to twenty weeks. This was followed by treatment 
with panobinostat which was purchased from Selleck 
Chemicals (Houston, TX, USA) at a concentration of 
1.5 mg/mL or vehicle (2% DMSO, 2% Tween 80, 48% 
PEG 300, 48% water) when papilloma size reaches 
to 1–2 mm and administered 3 times a week [Monday/
Wednesday/Friday (M/W/F)] in a volume of 10 mL/kg by 
intraperitoneal (i.p.) injection.
Statistics
Results are expressed as mean ± SEM. Statistical 
significance was determined by student’s t-test.
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